VASCEPA/VAZKEPA found in prespecified and post hoc analyses to reduce first and total primary endpoints by 26% and 35%, respectively, in REDUCE-IT patients with prior Myocardial Infarction 2021 ESC Guidelines on Cardiovascular Disease Prevention now include VAZKEPA in their recommendations, marking 20th inclusion in global medical societies’ guidelines DUBLIN, Ireland […]
Coronary/Structural Heart
Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF to Be Presented in Late Breaking Clinical Trials Session at the HFSA Annual Scientific Meeting
Full Results from REDWOOD-HCM Expand on Positive Topline Results of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy Additional Results from GALACTIC-HF Assess the Effect of Omecamtiv Mecarbil in Black Patients with Heart Failure with Reduced Ejection Fraction SOUTH SAN FRANCISCO, Calif., Aug. 31, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today […]
Hello Heart Achieves HITRUST CSF® Certification
Hello Heart is committed to meeting rigorous data privacy and security standards. MENLO PARK, Calif.–(BUSINESS WIRE)–Hello Heart, the leader in cardiovascular digital therapeutics, today announced that the company’s application, data storage, and supporting infrastructure has earned Certified status for information security by HITRUST. HITRUST CSF Certified status demonstrates that the […]
Vifor Pharma’s Ferinject® granted new recommendations in updated 2021 ESC heart failure guidelines
2021 European Society of Cardiology (ESC) guidelines for acute and chronic heart failure (HF) includes new recommendations on management of iron deficiency with Ferinject® (ferric carboxymaltose) in patients with HF Periodic screening for iron deficiency and the use of Ferinject® to reduce hospitalisation rates and improve HF symptoms are now recommended In addition, […]
Lexicon Welcomes New ESC Heart Failure Treatment Guidelines Establishing SGLT Inhibitors as Standard of Care
New guidelines from the European Society of Cardiology recommend addition of SGLT inhibitors to standard of care for patients with acute and chronic heart failure. Guidance underscores the benefits of SGLT inhibitors in significantly reducing risk of death due to cardiovascular causes or heart failure hospitalization. THE WOODLANDS, Texas, Aug. […]
Bayer Announces KERENDIA® (finerenone) Reduces the Risk of Cardiovascular Outcomes in New Phase III FIGARO-DKD Study in Adults With Chronic Kidney Disease (Stages 1-4) Associated With Type 2 Diabetes
FIGARO-DKD is the first contemporary cardiorenal outcomes trial with the majority of patients who had an eGFR ≥60 ml/min/1.73m2 to show cardiovascular benefit in chronic kidney disease associated with type 2 diabetes; patients were included in this study if they had UACR levels 30–5000 mg/g1 Additionally, results from FIDELITY, a prespecified […]
European observational study SANTORINI shows LDL-C levels remain higher than recommended goals and combination therapies are under-utilised in patients at very high or high cardiovascular risk
The SANTORINI study highlights that low-density lipoprotein cholesterol (LDL-C) levels remain substantially higher than recommended goals in patients who are at high- and very high-risk of cardiovascular events.1 Study data further demonstrate that combination therapies are being under-utilised, with nearly 73% of these patients not receiving combination therapy, despite their […]
GUIDE-HF Study Data Show Abbott’s CardioMEMS™ Device Can Improve Care for More Patients with Heart Failure
– The GUIDE-HF study examined the potential impact of Abbott’s CardioMEMS™ HF System, a small implantable pulmonary pressure sensor, in an expanded patient population not currently approved for the device – Data from the GUIDE-HF trial suggests CardioMEMS can improve care for more types of patients battling heart failure and […]
Quantum Genomics Presents Results from Phase IIb QUORUM Study of Firibastat in Heart Failure at the European Society of Cardiology Meeting
Firibastat is as efficient as the current standard of care (ramipril) in preventing the degradation of the left ventricular ejection fraction (primary endpoint) after myocardial infarction in full study population Firibastat demonstrated better efficacy compared to ramipril in severe patients with low ejection fraction Firibastat improved blood pressure profile in […]
CARMAT Announces a New Commercial Implant of Its Aeson® Artificial Heart at University Medical Center Schleswig-holstein in Kiel, Germany
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announces the third implant of its Aeson® bioprosthetic artificial heart in a commercial setting. This new […]
